|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: S100A6 |
Gene summary for S100A6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | S100A6 | Gene ID | 6277 |
| Gene name | S100 calcium binding protein A6 | |
| Gene Alias | 2A9 | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P06703 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6277 | S100A6 | GSM4909281 | Human | Breast | IDC | 1.96e-02 | 1.83e-01 | 0.21 |
| 6277 | S100A6 | GSM4909282 | Human | Breast | IDC | 3.82e-06 | 7.81e-02 | -0.0288 |
| 6277 | S100A6 | GSM4909285 | Human | Breast | IDC | 2.79e-03 | 1.18e-01 | 0.21 |
| 6277 | S100A6 | GSM4909286 | Human | Breast | IDC | 5.68e-37 | -4.33e-01 | 0.1081 |
| 6277 | S100A6 | GSM4909289 | Human | Breast | IDC | 2.15e-06 | -6.36e-01 | 0.1064 |
| 6277 | S100A6 | GSM4909291 | Human | Breast | IDC | 1.74e-29 | -9.37e-01 | 0.1753 |
| 6277 | S100A6 | GSM4909293 | Human | Breast | IDC | 1.52e-41 | -9.02e-01 | 0.1581 |
| 6277 | S100A6 | GSM4909294 | Human | Breast | IDC | 4.71e-20 | -7.41e-01 | 0.2022 |
| 6277 | S100A6 | GSM4909296 | Human | Breast | IDC | 1.56e-73 | -1.63e+00 | 0.1524 |
| 6277 | S100A6 | GSM4909297 | Human | Breast | IDC | 8.24e-12 | 2.96e-01 | 0.1517 |
| 6277 | S100A6 | GSM4909298 | Human | Breast | IDC | 5.31e-33 | -4.81e-01 | 0.1551 |
| 6277 | S100A6 | GSM4909299 | Human | Breast | IDC | 3.97e-06 | 2.46e-01 | 0.035 |
| 6277 | S100A6 | GSM4909301 | Human | Breast | IDC | 6.97e-83 | -1.69e+00 | 0.1577 |
| 6277 | S100A6 | GSM4909302 | Human | Breast | IDC | 6.34e-22 | -4.42e-01 | 0.1545 |
| 6277 | S100A6 | GSM4909303 | Human | Breast | IDC | 3.66e-19 | -1.07e+00 | 0.0438 |
| 6277 | S100A6 | GSM4909304 | Human | Breast | IDC | 3.93e-13 | -3.14e-01 | 0.1636 |
| 6277 | S100A6 | GSM4909306 | Human | Breast | IDC | 6.07e-27 | -6.12e-01 | 0.1564 |
| 6277 | S100A6 | GSM4909307 | Human | Breast | IDC | 3.04e-18 | -6.20e-01 | 0.1569 |
| 6277 | S100A6 | GSM4909308 | Human | Breast | IDC | 1.73e-47 | -8.30e-01 | 0.158 |
| 6277 | S100A6 | GSM4909311 | Human | Breast | IDC | 6.22e-58 | -1.19e+00 | 0.1534 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00481453 | Breast | Precancer | regulation of fibroblast proliferation | 12/1080 | 80/18723 | 2.03e-03 | 1.94e-02 | 12 |
| GO:00481443 | Breast | Precancer | fibroblast proliferation | 12/1080 | 81/18723 | 2.26e-03 | 2.12e-02 | 12 |
| GO:004814511 | Breast | IDC | regulation of fibroblast proliferation | 14/1434 | 80/18723 | 2.83e-03 | 2.48e-02 | 14 |
| GO:004814411 | Breast | IDC | fibroblast proliferation | 14/1434 | 81/18723 | 3.18e-03 | 2.68e-02 | 14 |
| GO:00481452 | Breast | DCIS | regulation of fibroblast proliferation | 13/1390 | 80/18723 | 5.80e-03 | 4.17e-02 | 13 |
| GO:00481442 | Breast | DCIS | fibroblast proliferation | 13/1390 | 81/18723 | 6.45e-03 | 4.58e-02 | 13 |
| GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
| GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
| GO:00481462 | Cervix | HSIL_HPV | positive regulation of fibroblast proliferation | 7/737 | 48/18723 | 2.57e-03 | 2.50e-02 | 7 |
| GO:00481454 | Cervix | HSIL_HPV | regulation of fibroblast proliferation | 9/737 | 80/18723 | 4.13e-03 | 3.53e-02 | 9 |
| GO:00481444 | Cervix | HSIL_HPV | fibroblast proliferation | 9/737 | 81/18723 | 4.49e-03 | 3.76e-02 | 9 |
| GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
| GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
| GO:00615641 | Colorectum | SER | axon development | 94/2897 | 467/18723 | 3.78e-03 | 3.13e-02 | 94 |
| GO:00074091 | Colorectum | SER | axonogenesis | 84/2897 | 418/18723 | 6.20e-03 | 4.49e-02 | 84 |
| GO:00074092 | Colorectum | MSS | axonogenesis | 105/3467 | 418/18723 | 4.32e-04 | 5.23e-03 | 105 |
| GO:00615642 | Colorectum | MSS | axon development | 115/3467 | 467/18723 | 5.33e-04 | 6.00e-03 | 115 |
| GO:00615643 | Colorectum | FAP | axon development | 106/2622 | 467/18723 | 1.98e-07 | 1.21e-05 | 106 |
| GO:00074093 | Colorectum | FAP | axonogenesis | 97/2622 | 418/18723 | 2.20e-07 | 1.30e-05 | 97 |
| GO:00074094 | Colorectum | CRC | axonogenesis | 81/2078 | 418/18723 | 3.60e-07 | 2.99e-05 | 81 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| S100A6 | SNV | Missense_Mutation | c.172N>A | p.Glu58Lys | p.E58K | P06703 | protein_coding | tolerated(1) | benign(0.007) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| S100A6 | insertion | Frame_Shift_Ins | novel | c.238_239insCACGGTCAACCTCTGAAAA | p.Leu80SerfsTer13 | p.L80Sfs*13 | P06703 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| S100A6 | SNV | Missense_Mutation | novel | c.221N>C | p.Val74Ala | p.V74A | P06703 | protein_coding | tolerated(0.26) | benign(0.006) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| S100A6 | SNV | Missense_Mutation | novel | c.22G>A | p.Ala8Thr | p.A8T | P06703 | protein_coding | deleterious(0.04) | possibly_damaging(0.865) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| S100A6 | SNV | Missense_Mutation | c.192N>T | p.Lys64Asn | p.K64N | P06703 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-BR-8081-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| S100A6 | SNV | Missense_Mutation | novel | c.67N>A | p.Glu23Lys | p.E23K | P06703 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-BR-8362-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | etoposide | PD |
| S100A6 | SNV | Missense_Mutation | c.32T>G | p.Leu11Arg | p.L11R | P06703 | protein_coding | deleterious(0.02) | benign(0.42) | TCGA-EM-A3AK-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |